Teva Pharmaceutical Industries Limited Stock Prediction and Forecast [TEVA]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 25 Oct 2025, 03:48 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Teva Pharmaceutical Industries Limited Stock Prediction and Forecast [TEVA]](https://i.ytimg.com/vi/DdGCELrgMVo/hqdefault.jpg)
AI-generated source summary
The analysis discusses Teva Pharmaceutical Industries, noting several negative signals but upgrading the analysis conclusion from a sell to a hold candidate. It identifies resistance at $19.68 and support at $16.83. The stock exhibits medium daily movements, indicating medium risk. A sell signal from a pivot top was found 12 days prior. Analyst ratings indicate a sell. The P/E ratio is -138.64. A suggested stop-loss is set at $17.91. Recent insider trading shows more sales than buys. Upward corrections may face resistance at $19.18 and $19.41. A breakout above these levels may issue buy signals, while a sell signal occurred from a pivot top on October 8, 2025. The trend suggests a potential change of 22.99% over the next 3 months with a possible return ranging from 22.99% to 35.93%. A 12-month analysis projects a change of -0.0951%, with performance fluctuating between -32.47% and 19.95%.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.